In another study published in 2016, ex vivo generated PCTS derived from murine PDX models of PDA were used for the prediction of patient response to clinically relevant anti-PDA chemotherapeutic agents, including gemcitabine, irinotecan, MEK inhibitor AZD6244 and AKT inhibitor MK2206 [48]. This evidence concerns the gene AKT1 and Patent ductus arteriosus.